GeoVax Highlights Peer-Reviewed Research Supporting Gedeptin(R) Potential to Enhance Cancer Immunotherapy Responses

Therapy to Enhance Checkpoint Inhibitor Responses and Activate Systemic Anti-Tumor Immunity ATLANTA, GA - June 8, 2026 ...

GeoVax Highlights Strategic Implications of Recent Gedeptin(R) Findings for Checkpoint-Resistant Cancers

Recent Publication and Growing Industry Focus on Immune-Priming Strategies Support Continued Evaluation of Gedeptin(R) as a ...
Targeted Oncology

Dr Rodriguez on Tolododekin Alfa in NSCLC

Tolododekin alfa (ANK-101) is a novel anchored immunotherapy that links interleukin-12 (IL-12) to aluminum hydroxide via an ...
Nature

Immune Checkpoint Inhibition in Advanced Cancer Treatment

Immune checkpoint inhibitors have transformed the management of advanced malignancies by releasing the brakes on antitumour T-cell responses. Agents targeting programmed cell death protein 1 (PD-1), ...
Nature

Immune Checkpoint Inhibition in Lung Cancer Toxicity Management

Immune checkpoint inhibitors have transformed the treatment landscape of advanced non-small cell lung cancer by unleashing antitumour T-cell responses through blockade of regulatory receptors. Despite ...
Technology Networks

Trispecific Antibody Targets Three Immune Checkpoints

L1, TIGIT, and LAG3 targeting in one reagent, enabling more efficient exploration of checkpoint interactions and immune ...
ascopubs.org

Translating Innovation Into Practice: Dissemination of Immune Checkpoint Inhibitors and Their Toxicity Management Across the Globe

Immune checkpoint inhibitors (ICIs) have redefined the therapeutic landscape of oncology, producing durable responses across multiple tumor types and treatment settings. However, widespread adoption ...